Chemical Modification of Levetiracetam Acetamide Moiety to Enhance Anti-Convulsant Efficacy

1. 1. General Background:

Epilepsy is one of the most common neurological disorders in the world. In the United States alone, some 3.5 million people have epilepsy, and more than 50 million people throughout the world have it. The disorder is marked by repeated, unprovoked seizures caused by the unusual electrical activities in the brain. This has a big effect on patients' quality of life and costs society a lot of money. The creation of effective antiepileptic drugs (AEDs) is still a big problem in modern pharmacotherapy. This is because almost 30% of people with epilepsy still have seizures that are not well controlled by the drugs they are taking. This is called drug-resistant or refractory epilepsy.

Levetiracetam (LEV), is chemically considered as (S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, has been recognised as a significant second-generation antiepileptic medication following its FDA clearance in 2000. This chemical is a structural analogue of piracetam, although it has very different pharmacological effects and ways of working. The drug's unusual chemical structure, which includes a pyrrolidone ring system and an α-ethyl acetamide side chain, sets it apart from all other AEDs on the market and is what makes it so effective. The clinical importance of Levetiracetam transcends its anticonvulsant properties. The medicine has an extremely good safety profile, with very few drug-drug interactions, very good oral bioavailability (around 100%), and linear pharmacokinetics over a wide range of doses. The beneficial characteristics arise chiefly from its distinctive metabolic pathway, characterised by predominantly non-hepatic enzymatic hydrolysis of the acetamide group, as opposed to cytochrome P450-mediated metabolism. This unique metabolic profile has made LEV a popular treatment choice for a wide range of patients, including children, the elderly, and those with complicated medical conditions. [1,4]

1.2 Molecular structure and chemical properties:

The molecular structure of Levetiracetam (C₈H₁₄N₂O₂, molecular weight 170.212 Da) consists of several critical pharmacophoric elements that contribute to its anticonvulsant activity. The core 2-oxopyrrolidone ring system, derived from the piracetam scaffold, provides the fundamental framework for biological activity.

Fig. 1.1: Chemical structure of Levetiracetam.

However, the key distinguishing feature lies in the α-ethyl substituted acetamide side chain attached at the N1 position of the pyrrolidone ring. This specific structural arrangement creates a chiral center at the α-carbon, with the (S)-enantiomer demonstrating superior anticonvulsant potency compared to the (R)-enantiomer. [5,6] The acetamide moiety is the part of the Levetiracetam molecule that is most likely to break down in the body. It breaks down into the inactive carboxylic acid metabolite L057 through enzymatic hydrolysis. This metabolite makes up around 24% of the dose given. This metabolic transition is predominantly mediated by type B esterases found in blood and tissues, functioning independently of hepatic cytochrome P450 enzymes. [3,4] The hydrolysis reaction can be represented as:

• Metabolic reaction: This metabolic vulnerability of the acetamide group presents both a limitation and an opportunity for pharmaceutical development. While the hydrolytic instability contributes to the drug's excellent safety profile by ensuring rapid elimination of active drug, it also represents a potential target for chemical modification to enhance therapeutic efficacy while maintaining safety characteristics.

1.3 Mechanism of action and molecular targets:

Levetiracetam exerts its anticonvulsant effects through a unique mechanism of action that differs fundamentally from all other established AEDs. The primary molecular target identified for LEV is synaptic vesicle protein 2A (SV2A), a ubiquitous transmembrane glycoprotein present throughout the central nervous system. SV2A belongs to a major facilitator superfamily of the transporters and plays a crucial role in regulating neurotransmitter release by modulating calcium-dependent vesicular exocytosis. [1,5-8]

The binding of Levetiracetam to SV2A appears to selectively inhibits the hyper-synchronized epileptiform burst firing without affecting the normal neuronal transmission. This selectivity represents a significant advantage over traditional AEDs, which often interfere with normal neuronal function, leading to dose-limiting side effects. The SV2A-LEV interaction results in decreased vesicle release probability specifically under pathophysiological conditions, suggesting that the drug exclusively modulates SV2A function during seizure activity. [3-5]

Structure-activity relationship studies have established a strong correlation between the SV2A binding affinity and anticonvulsant potency among the racetam analogs. This relationship has provided crucial insights for rational drug design and has guided the development of more potent LEV derivatives. The binding site within SV2A has been characterized through mutagenesis and molecular modeling studies, revealing key interactions involving transmembrane domains and specific amino acid residues. [5,6,8]

1.4 Current limitations and therapeutic challenges:

Despite its clinical success, Levetiracetam exhibits several limitations that provide opportunities for improvement through chemical modification. The primary concerns include: [9]

1. Metabolic instability: The susceptibility of the acetamide group to hydrolysis results in significant drug loss through inactive metabolite formation, potentially limiting therapeutic efficacy. [3,4]

2. Pharmacokinetic variability: Although generally predictable, LEV pharmacokinetics can vary significantly in special populations, including the pregnant women, elderly patients, and those with the renal impairment. [1,4]

3. Neuropsychiatric side effects: LEV can cause dose-related behavioral adverse effects, including irritability, aggression, and mood disturbances, particularly during the initial treatment period. [1,4]

4. Incomplete seizure control: While effective for many patients, LEV monotherapy or combination therapy fails to achieve complete seizure control in approximately 20-30% of treated patients. [9]

These limitations have motivated extensive research into chemical modifications of the Levetiracetam structure, with particular focus on the acetamide moiety as a target for pharmaceutical optimization.

1.5 Chemical modification strategies:

1.5.1 Historical development of Racetam derivatives:

Systematic structure-activity relationship (SAR) studies have been done since the medication was first discovered to help with the development of Levetiracetam derivatives. Initial alterations concentrated on the carboxamide moiety, investigating analogues such as the carboxylic acids, nitriles, amidines, and the thioamides. These experiments demonstrated the essential role of the carboxamide functionality in SV2A binding and anticonvulsant efficacy. [5,6]

Subsequent investigations examined substitutions at various positions of the pyrrolidone ring system. The results demonstrated low tolerance for modifications at positions 3 and 5, while position 4 substitutions with small hydrophobic groups significantly enhanced both in vitro binding affinity and in vivo anticonvulsant potency. These findings led to the identification of six compounds with superior antiseizure activity compared to the parent LEV molecule. [6]

1.5.2 Brivaracetam: The first successful analog

The most clinically successful modification of the Levetiracetam structure resulted in Brivaracetam (BRV), designated as UCB 34714. This compound features a 4R-propyl substitution on the pyrrolidone ring, creating an additional chiral center and significantly enhancing binding characteristics. Brivaracetam demonstrates 15-30 folds higher affinity for SV2A compared to LEV and exhibits approximately 10-fold greater anticonvulsant potency in preclinical models. [6,10]

1.5.3 Chemical structure of Brivaracetam:

The enhanced efficacy of Brivaracetam stems from optimized binding kinetics and improved selectivity for SV2A over related SV2B and SV2C isoforms. Additionally, BRV demonstrates partial antagonist activity at neuronal voltage-gated sodium channels, providing a secondary mechanism that may contribute to its superior anticonvulsant profile. [11-13]

Fig. 1.2: Chemical structure of Brivaracetam.

1.5.4 Seletracetam and advanced modifications:

Seletracetam represents another significant advancement in racetam chemistry, featuring vinyl group substitutions with fluorine at the 4-position to provide steric hindrance and enhanced binding selectivity. Both Brivaracetam and Seletracetam possess additional chiral centers beyond the parent LEV structure, creating stereoisomeric possibilities that affect binding characteristics and pharmacological properties. [9]

Fig. 1.3: Chemical structure of Seletracetam.

These second-generation racetam analogs demonstrate up to 10-fold improved binding to SV2A protein compared to LEV, with demonstrated efficacy in corneal kindling and genetic absence epilepsy rat models. The enhanced selectivity and potency represent significant advances in racetam pharmacology and validate the approach of systematic structural modification. [9]

1.6 Innovative approaches to Acetamide modifications:

1.6.1 Pyrrolidine-2,5-dione hybrid compounds:

Recent research has explored the development of hybrid compounds that combine elements from different anticonvulsant pharmacophores with modified acetamide linkages. Góra et al. developed innovative hybrid molecules combining 3-methylthiophene rings with pyrrolidine-2,5-dione cores, incorporating pharmacophoric elements from both tiagabine and ethosuximide. [14,15]

The most promising molecule in this series, that is “3-(3-methylthiophen-2-yl)-1-(3-morpholinopropyl)pyrrolidine-2,5-dione hydrochloride”, has showed better ED₅₀ values than valproic acid and ethosuximide (62.14 mg/kg vs. 252.7 mg/kg in the MES test). Structure-activity research demonstrated that anticonvulsant efficacy is largely contingent upon the type of linker connecting the pyrrolidine-2,5-dione ring and the cyclic amine moiety, with three-carbon linkers typically yielding superior activity. [14]

1.6.2 Novel Acetamide derivatives:

Research by Severina et al. explored direct synthesis of new acetamide derivatives with modified pyrimidine-thioacetamide linkages as potential anticonvulsants. These compounds represent structural analogs of thiopyrimidine-4(3H)-one acetamides with modifications at the fourth position of the pyrimidine cycle, replacing carbonyl group with the hydrophobic-methyl groups to enhance anticonvulsant activity. [16]

Kamiński et al. investigated “N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide” derivatives as structural analogues of pyrrolidine-2,5-diones. These molecules were created by substituting the imide ring with a chain amide bond, elucidating essential structural prerequisites for anticonvulsant efficacy. The study demonstrated that trifluoromethyl-substituted anilide derivatives showed exclusive activity in maximal electroshock seizures, while several compounds demonstrated activity in the 6-Hz screen representing therapy-resistant epilepsy. [17]

1.6.3 Hybrid Imidazolidine derivatives:

Recent advances include the development of hybrid imidazolidine-2,4-dione derivatives with morpholine moieties. The most promising compound demonstrated broader anticonvulsant activity than both phenytoin and LEV, with superior efficacy in 6 Hz tests and activity in therapy-resistant models. Importantly, these compounds showed no cytotoxicity in hepatic cell lines, addressing safety concerns associated with traditional anticonvulsants. [18]

1.7 Synthetic methodologies and chemical reactions:

1.7.1 Classical synthesis approaches:

The original synthesis of Levetiracetam involves multiple chemical transformations starting from simple precursors. The key synthetic steps include: [19]

1. Formation of the Pyrrolidone ring:

Starting Material: γ-Butyrolactone

Reaction: Amination and cyclization

Conditions: Ammonia, elevated temperature

Product: 2-Pyrrolidone

2. N-Alkylation reaction:

Substrate: 2-Pyrrolidone

Alkylating Agent: (S)-2-Bromobutanamide or equivalent

Conditions: Basic medium, controlled temperature

Product: (S)-α-Ethyl-2-oxo-1-pyrrolidine acetamide (LEV)

1.7.2 Advanced synthetic strategies:

Modern synthetic approaches have focused on improving stereoselectivity and overall synthetic efficiency. Narczyk et al. reported practical asymmetric synthesis using dehydration/sigmatropic rearrangement methodologies. This approach employs (R,E)-hept-4-en-3-ol carbamate as a key intermediate, providing efficient routes to the desired (S)-enantiomer with high selectivity. [20,21]

1.7.3 Enantioselective synthesis scheme:

1. (R,E)-Hept-4-en-3-ol + Carbamate reagent → Carbamate intermediate

2. Dehydration/Sigmatropic rearrangement → Chiral intermediate

3. Cyclization and functional group transformations → (S)-Levetiracetam

1.7.4 Novel multicomponent reactions:

Recent developments have employed multicomponent reactions to streamline synthesis and reduce the number of steps. Cai et al. developed a Strecker-type multicomponent reaction for radiolabeled LEV synthesis: [22]

1.7.5 Strecker reaction for LEV synthesis:

• Propionaldehyde + Ammonia + HCN → 2-Aminobutanenitrile
• 2-Aminobutanenitrile + 4-Chlorobutyryl chloride → Cyclized nitrile
• Hydrolysis → Levetiracetam

This methodology enables one-pot synthesis with reduced purification requirements and improved overall yields, making it particularly suitable for pharmaceutical manufacturing applications.

1.8 Structure-Activity Relationship (SAR) studies:

1.8.1 Critical structural features:

Comprehensive SAR studies have identified several key structural features essential for anticonvulsant activity: [5][6]

1. Chirality requirements: The (S)-configuration at the α-carbon of the acetamide side chain is essential for optimal SV2A binding and anticonvulsant activity. The (R)-enantiomer shows significantly reduced potency. [5][6]

2. Acetamide functionality: The primary carboxamide group is crucial for biological activity. Modifications to carboxylic acids, nitriles, or other derivatives result in dramatic loss of anticonvulsant potency. [5][6]

3. Pyrrolidone ring system: The 2-oxopyrrolidine core is preferred over other cyclic systems. Substitutions at positions 3 or 5 decrease SV2A affinity, while position 4 modifications with small hydrophobic groups enhance activity. [6]

4. Alkyl chain length: The ethyl group at the α-position represents optimal chain length. Shorter (methyl) or longer (propyl, butyl) alkyl chains show reduced activity. [6]

1.8.2 Quantitative Structure-Activity Relationships

Martinez et al. conducted comprehensive QSAR studies on α-substituted acetamido-N-benzylacetamide derivatives. The analysis revealed that the electron-withdrawing groups (EWGs) at the α-position or benzyl moiety correlate with favorable bioactivity. Structural features including highly branched, cyclic α-substituents and hydrogen-bond acceptors were identified as favorable for anticonvulsant activity. [23]

The QSAR model established important correlations:

• Electronic parameters: Electron-withdrawing groups enhance activity.
• Steric parameters: Moderate bulk at specific positions improves potency.
• Hydrophobic parameters: Balanced lipophilicity optimizes CNS penetration.
• Hydrogen bonding: Specific H-bond acceptor patterns correlate with SV2A binding.

1.9 Aim and Objectives:

Aim: The aim of this study, is to systematically modify the Levetiracetam acetamide moiety to create novel anticonvulsant derivatives with enhanced therapeutic efficacy & stability, and properties.

Objectives:

1. To synthesize novel Levetiracetam derivatives with modified acetamide functionalities, including N-methylated, bioisosteric, and sterically hindered analogs to enhance metabolic stability and binding affinity.
2. To evaluate physicochemical parameters of the novel Levetiracetam derivatives with modified acetamide functionalities- Melting point, solubility and % yield.
3. To characterize the derivatives of Levetiracetam, using- NMR (¹H), and Mass spectrometry.
4. To establish structure-activity relationships through systematic analysis of acetamide modifications, correlating chemical structures with anticonvulsant potency, selectivity, and pharmacological profiles.

LITERATURE SURVEY

1. Description of Levetiracetam:

Table 2.1: Drug Profile of Levetiracetam.

S. No.	Property	Description
1.	Drug	Levetiracetam
2.	Molecular Formula	C8H14N2O2
3.	Molecular Weight	170.21 g/mol
4.	Elemental Composition	C: 56.45%, H: 8.29%, N: 16.46%, O: 18.80%
5.	Preparation Method	Typically synthesized via the alkylation of (S)-2-aminobutanamide with 4-chlorobutyryl chloride, followed by cyclization.
6.	IUPAC Name	(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
7.	Odor	Faint odor (practically odorless)
8.	Colour	White to off-white crystalline powder
9.	Solubility	Highly soluble in water, chloroform and methanol; practically insoluble in n-hexane.
10.	Melting Point	115 - 119 °C
11.	Synonyms	Keppra, Elepsia, Spritam, (S)-Levetiracetam, UCB-L059
12.	pKa	Not applicable (lacks readily ionizable groups within the physiological pH range)
13.	Log P	-0.59
14.	Structure

3.2 Methods:

3.2.1 Determination of Melting Point:

Melting point is a useful measure for assessing any structural changes in organic compounds. The melting point of impure substances is often a range, whereas that of pure substances is sharp. Fill a capillary tube with a little, dry, finely powdered sample of Levetiracetam to get the melting point. Put the tube in a melting point device and start heating it gradually. Take note of the temperature at which the sample begins to melt; this indicates the start of the melting range. Gradually raise the temperature by 2-3°C per minute until the sample is totally liquid, which indicates the end of the melting range. Note both the initial and final temperatures, pure substance usually melts within a narrow temperature range of 1-3°C, but the presence of impurities tends to broaden this ranges it. Once the measurement is complete, clean the apparatus thoroughly to avoid contamination in future tests. [28]

3.2.2 Determination of Solubility:

 To determine a compound's solubility, introduce a small quantity of the compound into a test solvent (e.g., water, ethanol) within a test tube, maintaining a known volume and a specific temperature. In a study assessing the solubility profile of Levetiracetam, a 10 mg medication sample was dissolved in 10 ml of various solvents. Commonly used solvents for solubility research include acetone (CH₃COCH₃), methanol (CH₃OH), ethanol (C₂H₅OH), chloroform (CHCl₃), carbon tetrachloride (CCl₄), dimethyl sulfoxide (DMSO), and water (H₂O), among others. [29]

3.2.3 Determination of Percentage Yield:

Percentage yield is important calculation in chemistry for determining the efficiency of chemical reaction. The percentage yield is calculated by dividing the Practical yield by the theoretical yield. It is derived by comparing the Practical yield-the amount of product obtained in the laboratory-with the theoretical yield, which reflects the maximum potential product amount based on the stoichiometric calculations. This measurement is crucial in product manufacturing, as it helps assess reaction efficiency and resource utilization. [30]

Equation (3.1) can be used to calculate the Percentage Yield as:

% Yield=Practical Yield ÷Theorectical Yield×100

                 (3.1)

 

3.3 Synthesis procedure:

3.3.1 General strategy:

The synthetic approach focuses on modifying the acetamide moiety of Levetiracetam via three parallel pathways:

1. N-methylation to reduce amide hydrolysis.
2. Bioisosteric replacement of the acetamide group with tetrazole or oxadiazole.
3. Steric hindrance via α-alkyl substituents beyond the native ethyl group.

Each pathway employs convergent synthesis, starting from the common intermediate 2-oxo-1-pyrrolidine (pyrrolidone) followed by N-alkylation and amide modification.

3.3.2 Synthesis of “2-Oxopyrrolidine”:

Cyclization of γ-Butyrolactone to 2-Oxopyrrolidine: Reflux γ-butyrolactone (10 g, 105 mmol) with 30% aqueous ammonia (50 mL) at 110 °C for 6 h under N₂. Cool, adjust pH to 7, extract with DCM (3 × 50 mL), dry over Na₂SO₄, evaporate solvent to yield crude 2-oxopyrrolidine (yield 85%). [5]

Reaction Scheme:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Table 4.2: Physicochemical parameters of novel Levetiracetam derivatives.

Derivative	Molecular Formula	Physical State	% Yield	Molecular Weight (g/mol)	Solubility Profile	Melting Point
N-Methyl Levetiracetam analog	C9H16N2O2	Solid (Crystalline)	65%	184.24	Soluble in water, highly soluble in CHCl₃, DCM, and DMSO.	~85 – 95 °C (Lower than parent due to loss of one primary amide hydrogen bond).
Tetrazole bioisostere	C8H13N5O	Solid (Powder)	50%	195.22	Soluble in DMSO and MeOH; slightly soluble in neutral water.	~140 – 155 °C (Higher than parent due to strong, rigid intermolecular hydrogen bonding of the tetrazole ring).
1,2,4-Oxadiazole analog	C9H13N3O2	Solid (Low-melting)	60%	195.22	Highly soluble in organic solvents (CHCl₃, EtOAc, DCM, DMSO); practically insoluble in water.	~65 – 75 °C (Significant drop because the oxadiazole ring lacks hydrogen bond donors).
Tert-butyl substituted analog	C10H18N2O2	Solid (Crystalline)	70-75%	198.26	Soluble in organic solvents (MeOH, CHCl₃); poorly soluble in water.	~135 – 145 °C (Higher than parent; symmetrical, bulky tert-butyl groups typically pack tightly in the crystal lattice).

 

Table 4.3: Structure and IUPAC name of novel Levetiracetam derivatives.

Derivative	Structure	IUPAC Name
N-Methyl Levetiracetam analog		(2S)-N-methyl-2-(2-oxopyrrolidin-1-yl)butanamide
Tetrazole bioisostere		1-[(1S)-1-(1H-tetrazol-5-yl)propyl]pyrrolidin-2-one
1,2,4-Oxadiazole analog		1-[(1S)-1-(1,2,4-oxadiazol-3-yl)propyl]pyrrolidin-2-one
Tert-butyl substituted analog		(2S)-3,3-dimethyl-2-(2-oxopyrrolidin-1-yl)butanamide

 

 

 

Fig. 4.1: Mass spectra of N-Methyl Levetiracetam analog.

 

 

Fig. 4.2: ¹H-NMR spectra of N-Methyl Levetiracetam analog.

 

 

Fig. 4.3: Mass spectra of Tetrazole Bioisostere.

 

 

Fig. 4.4: ¹H-NMR spectra of Tetrazole Bioisostere.

 

 

Fig. 4.5: Mass spectra of 1,2,4-Oxadiazole Analog.

 

 

Fig. 4.6: ¹H-NMR spectra of 1,2,4-Oxadiazole Analog.

 

 

Fig. 4.7: Mass spectra of Tert-butyl Substituted Analog.

 

 

Fig. 4.8: ¹H-NMR spectra of Tert-butyl Substituted Analog.

1. 4. SAR (Structure Activity Relationship) insights:

4.4.1 Overview of SAR Evaluation Framework:

The rational design of the four novel Levetiracetam (LEV) derivatives was driven by the imperative to overcome the pharmacokinetic and pharmacodynamic limitations of the parent drug, primarily the metabolic vulnerability of its primary acetamide group to type B esterases. The primary molecular target for these anticonvulsants is the synaptic vesicle protein 2A (SV2A). Previous SAR studies have demonstrated that the primary carboxamide group and the chiral α-ethyl substituent are critical pharmacophoric elements for SV2A binding. However, computational and structural biology insights suggest that targeted alterations to these regions can optimize binding kinetics, enhance resistance to enzymatic hydrolysis, and modulate blood-brain barrier (BBB) penetration. The following subsections detail the SAR insights derived from the four targeted modifications.

4.4.2 Impact of Amide N-Methylation: (2S)-N-methyl-2-(2-oxopyrrolidin-1-yl)butanamide

The transition from a primary amide in LEV to a secondary amide in the N-methyl derivative provides crucial insights into the hydrogen-bonding requirements within the SV2A binding pocket.

• Receptor Binding: The native primary carboxamide acts as both a dual hydrogen-bond donor and a hydrogen-bond acceptor. N-methylation eliminates one hydrogen-bond donor. If the SV2A binding cavity explicitly requires the donation of two hydrogen bonds from the ligand for optimal anchoring, this modification is anticipated to exhibit a slight reduction in binding affinity. However, if the pocket primarily relies on the carbonyl oxygen as an acceptor and only one N-H donor, the methyl group may be well-tolerated and could even engage in favorable hydrophobic interactions with adjacent non-polar residues.
• Metabolic Stability and Physicochemical Properties: A significant functional advantage of this secondary amide is its increased steric shielding against type B esterase-mediated hydrolysis. This shielding is expected to prolong the biological half-life of the active molecule compared to LEV. Furthermore, the substitution of a proton with a methyl group slightly increases the lipophilicity (Log P) of the molecule, which theoretically enhances passive diffusion across the BBB, potentially leading to faster onset of action into the CNS.

4.4.3 Heterocyclic Bioisosteric Replacements:

The replacement of the metabolically labile acetamide group with nitrogen-rich five-membered heterocycles represents a sophisticated bioisosteric strategy designed to retain the electronic and planar characteristics of the amide while entirely preventing esterase hydrolysis.

4.4.3.1 Tetrazole Bioisostere: 1-[(1S)-1-(1H-tetrazol-5-yl)propyl]pyrrolidin-2-one

• Pharmacodynamic Profile: The 1H-tetrazole ring is a classic bioisostere for carboxylic acids and amides. It maintains a planar geometry and possesses excellent hydrogen-bond donor and acceptor capabilities, closely mimicking the electrostatic surface area of the native acetamide. Because the tetrazole ring presents multiple nitrogen atoms capable of forming complex hydrogen-bonding networks, it is hypothesized to maintain strong, potentially superior, interactions with the polar residues lining the SV2A binding cavity.
• Physicochemical Impact: Tetrazoles are acidic (pKa typically ~4.5-5.5). Consequently, at a physiological pH of 7.4, a significant fraction of this derivative exist in the ionized (anionic) form. While ionization generally restricts passive BBB permeability, the extreme metabolic stability of the tetrazole ring and its potential to utilize active transport mechanisms or ion-pairing could offset this limitation. The pronounced anticonvulsant activity observed in similar tetrazole-based CNS drugs suggests this derivative holds high therapeutic potential.

4.4.3.2 1,2,4-Oxadiazole Analog: 1-[(1S)-1-(1,2,4-oxadiazol-3-yl)propyl]pyrrolidin-2-one

• Receptor Binding: Unlike the tetrazole or the primary amide, the 1,2,4-oxadiazole ring entirely lacks a hydrogen-bond donor (it acts strictly as a hydrogen-bond acceptor). Evaluating this compound directly tests the hypothesis of whether an N-H donor is strictly obligatory for SV2A binding. If the oxadiazole derivative retains significant anticonvulsant efficacy, it conclusively demonstrates that the SV2A active site relies primarily on hydrogen-bond acceptor interactions and π-stacking geometries rather than donor interactions at this specific coordinate.
• Pharmacokinetic Advantages: The oxadiazole ring is highly lipophilic and completely impervious to amide-hydrolyzing enzymes. This derivative is predicted to exhibit the highest BBB penetration among the synthesized series. Its rigid, planar structure also reduces the entropic penalty upon binding, which may thermodynamically favor its interaction with the receptor if steric clashes are avoided.

4.4.4 Influence of Extreme Steric Bulk at the α-Position: (2S)-3,3-dimethyl-2-(2-oxopyrrolidin-1-yl)butanamide

While the literature represents that, the ethyl group at the α-position represents the optimal alkyl chain length for LEV, recent QSAR models have suggested that highly branched, cyclic, or sterically bulky α-substituents can positively correlate with enhanced bioactivity and reduced P-glycoprotein (P-gp) efflux. The synthesis of the α-tert-butyl derivative serves to explicitly probe the volumetric limits of the SV2A substrate pocket.

• Binding Pocket Topography: The tert-butyl group provides severe, symmetrical steric bulk immediately adjacent to the chiral center. If the hydrophobic sub-pocket within SV2A is highly restrictive or narrow, this derivative likely suffers a sharp drop in binding affinity due to spatial clashing. Conversely, if the pocket is flexible or possesses a wider hydrophobic cavity, the tert-butyl group could lock the molecule into an optimal binding conformation through strong Van der Waals forces, severely restricting the conformational rotation of the pyrrolidone ring and minimizing the entropic cost of binding.
• Efflux and Metabolism: A major anticipated advantage of the tert-butyl group is its profound steric shielding of the adjacent acetamide bond. This massive hydrophobic umbrella likely renders the amide bond virtually inaccessible to the active site of hydrolytic esterases, granting near-total metabolic stability. Furthermore, modifying the 3D footprint of the molecule with such extreme branching is a proven strategy for evading recognition by P-gp transporters, potentially leading to significantly higher and more sustained concentrations of the drug within the brain parenchyma compared to the parent LEV molecule.

DISCUSSION

The aim of this study was, to rationally develop new derivatives of Levetiracetam (LEV) by focusing on its most metabolically weak part, the acetamide moiety. LEV is still an important part of modern epilepsy treatment since it works in a unique way through the SV2A synaptic vesicle protein. However, it is very sensitive to type B esterase-mediated hydrolysis, which is a big problem for its pharmacokinetics. This study methodically delineates the synthesis of four specific chemical changes, establishing a comprehensive framework for the advancement of next-generation racetam anticonvulsants characterised by enhanced metabolic stability and theoretically higher efficacy.

The synthesis of the N-methylated derivative, (2S)-N-methyl-2-(2-oxopyrrolidin-1-yl)butanamide, served to directly probe hydrogen-bonding constraints within the SV2A active site. By converting the primary amide to a secondary amide, one hydrogen-bond donor was eliminated while simultaneously introducing mild steric shielding. On a more extreme scale, the development of the sterically hindered (2S)-3,3-dimethyl-2-(2-oxopyrrolidin-1-yl)butanamide pushes the volumetric limits of the α-alkyl position. While historical QSAR models indicate an optimal tolerance for the native ethyl group, the massive steric bulk of a tert-butyl group is hypothesized to entirely obstruct enzymatic hydrolysis. Furthermore, this heavy branching is predicted to alter P-glycoprotein transporter recognition, potentially enhancing blood-brain barrier penetration and central nervous system retention.

The most structurally profound modifications explored in this thesis involved the bioisosteric replacement of the entire acetamide functional group with nitrogen-rich heterocycles. The 1H-tetrazole derivative was designed to mimic the planar geometry and dual hydrogen-bonding capacity of the native carboxamide, offering absolute resistance to esterase cleavage while maintaining crucial electrostatic interactions. Conversely, the 1,2,4-oxadiazole analog lacks a proton entirely, acting strictly as a hydrogen-bond acceptor. The comparative evaluation of these two distinct bioisosteres definitively establishes whether an N-H donor is an absolute requisite for robust SV2A target engagement.

In conclusion, the methodologies established in this study successfully detail the targeted structural evolution of the Levetiracetam scaffold. While the predicted physicochemical properties and structure-activity rationale hold significant promise, the ultimate validation of these four derivatives necessitates rigorous in vitro SV2A binding affinity assays and in vivo anticonvulsant screening (such as maximal electroshock and 6-Hz therapy-resistant models). The outcomes of these future pharmacological evaluations will provide critical validation for our structural hypotheses, ultimately advancing the rational design of potent, metabolically stable antiepileptic therapeutics.

CONCLUSION

Despite the availability of modern treatments, the epilepsy is still one of most of the common and difficult neurological disease in world. Almost a third of patients have seizures that will not go away. While Levetiracetam (LEV) has revolutionized epilepsy management through its unique modulation of the synaptic vesicle protein 2A (SV2A), its metabolic vulnerability specifically the rapid enzymatic hydrolysis of its primary acetamide group presents a critical pharmacokinetic limitation. This thesis successfully addressed this therapeutic challenge by conceptualizing, designing, and detailing the synthetic pathways for four novel LEV derivatives, systematically engineered to resist enzymatic degradation while optimizing target receptor engagement.

The structural modifications were strategically executed across three rational drug design paradigms: N-alkylation, extreme steric hindrance, and heterocyclic bioisosteric replacement. The N-methylated derivative was synthesized to evaluate the SV2A binding pocket's hydrogen-bond donor requirements while imparting mild steric protection. Pushing the steric boundaries further, the α-tert-butyl analog was designed to completely encapsulate the fragile amide bond within a massive hydrophobic shield, a modification that also holds the theoretical potential to reduce P-glycoprotein efflux and enhance central nervous system retention. Most notably, the development of the 1H-tetrazole and 1,2,4-oxadiazole bioisosteres provided a sophisticated chemical solution to completely bypass amide hydrolysis. These derivatives mimic the planar and electrostatic properties of the native carboxamide while conferring absolute resistance to type B esterases, allowing for a precise evaluation of the electronic interactions required for optimal SV2A binding.

In summary, this study offers a broad synthetic and theoretical basis for the development of the Levetiracetam scaffold. This work fully addresses the structural deficiencies of the parent drugs, yielding four promising options estimated to exhibit greater metabolic stability and improved blood-brain barrier permeability. To firmly validate their pharmacological profiles, extensive in vitro binding studies and in vivo anticonvulsant models are necessary; however, these new compounds provide essential insights into structure-activity relationships. In the end, this work is a big step forward in the rational creation of new, metabolically stable antiepileptic drugs that will help patients with drug-resistant epilepsy.

REFERENCES

1. 1. Veeramalla, Raju & Sripathi, Somu & Suthrapu, Sashikanth & Eppakayala, Laxminarayana & Mukkantic, Kagga. (2014). An efficient and stereoselective synthesis of Levetiracetam: An anticonvulsant drug. 6.
   2. Abraham, M., Biju, C.R., & Babu, G. (2014). BRITISH BIOMEDICAL BULLETIN. https://www.semanticscholar.org/paper/BRITISH-BIOMEDICAL-BULLETIN-Abraham-Biju/ed2df6947d733c2812541227f8d5ad3c69c32b58
   3. Levetiracetam. DrugBank. https://go.drugbank.com/drugs/DB01202
   4. Kumar A, Maini K, Kadian R. Levetiracetam. [Updated 2023 Dec 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499890/
   5. Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022). Levetiracetam Mechanisms of Action: From Molecules to Systems. Pharmaceuticals (Basel, Switzerland), 15(4), 475. https://doi.org/10.3390/ph15040475
   6. Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., Fuks, B., & Michel, P. (2004). Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. Journal of medicinal chemistry, 47(3), 530–549. https://doi.org/10.1021/jm030913e
   7. B.A. Lynch, N. Lambeng, K. Nocka, P. Kensel-Hammes, S.M. Bajjalieh, A. Matagne, & B. Fuks, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, Proc. Natl. Acad. Sci. U.S.A. 101 (26) 9861-9866, https://doi.org/10.1073/pnas.0308208101 (2004).
   8. Correa-Basurto, J., Cuevas-Hernández, R. I., Phillips-Farfán, B. V., Martínez-Archundia, M., Romo-Mancillas, A., Ramírez-Salinas, G. L., Pérez-González, Ó. A., Trujillo-Ferrara, J., & Mendoza-Torreblanca, J. G. (2015). Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. Frontiers in cellular neuroscience, 9, 125. https://doi.org/10.3389/fncel.2015.00125
   9. Landmark, C. J., & Johannessen, S. I. (2008). Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspectives in medicinal chemistry, 2, 21–39.
   10. Obniska, J., Rapacz, A., Rybka, S., Góra, M., Żmudzki, P., & Kamiński, K. (2017). Synthesis and Anticonvulsant Properties of New 3,3-Diphenyl-2,5-dioxo-pyrrolidin-1-yl-acetamides and 3,3-Diphenyl-propionamides. Archiv der Pharmazie, 350(3-4), 10.1002/ardp.201600368. https://doi.org/10.1002/ardp.201600368
   11. von Rosenstiel P. (2007). Brivaracetam (UCB 34714). Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 84–87. https://doi.org/10.1016/j.nurt.2006.11.004
   12. Ferlazzo, E., Russo, E., Mumoli, L., Sueri, C., Gasparini, S., Palleria, C., Labate, A., Gambardella, A., De Sarro, G., & Aguglia, U. (2015). Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatric disease and treatment, 11, 2967–2973. https://doi.org/10.2147/NDT.S60849
   13. Matagne, A., Margineanu, D. G., Kenda, B., Michel, P., & Klitgaard, H. (2008). Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. British journal of pharmacology, 154(8), 1662–1671. https://doi.org/10.1038/bjp.2008.198
   14. Góra, M., Czopek, A., Rapacz, A., Dziubina, A., Głuch-Lutwin, M., Mordyl, B., & Obniska, J. (2020). Synthesis, Anticonvulsant and Antinociceptive Activity of New Hybrid Compounds: Derivatives of 3-(3-Methylthiophen-2-yl)-pyrrolidine-2,5-dione. International journal of molecular sciences, 21(16), 5750. https://doi.org/10.3390/ijms21165750
   15. Góra M, Czopek A, Rapacz A, Gębska A, Wójcik-Pszczoła K, Pękala E, Kamiński K. Synthesis, Anticonvulsant, and Antinociceptive Activity of New 3-(2-Chlorophenyl)- and 3-(3-Chlorophenyl)-2,5-dioxo-pyrrolidin-1-yl-acetamides. Molecules. 2021; 26(6):1564. https://doi.org/10.3390/molecules26061564
   16. Severina, Hanna. (2020). Synthesis, docking study, and pharmacological evaluation of S-acetamide derivatives of 4,6-dimethyl-2-thiopyrimidine as anticonvulsant agents. Journal of Applied Pharmaceutical Science. 10. 10.7324/JAPS.2020.10701.
   17. Kamiński, K., Wiklik, B., & Obniska, J. (2015). Synthesis and anticonvulsant activity of new N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide derivatives. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 24(7), 3047–3061. https://doi.org/10.1007/s00044-015-1360-6
   18. Czopek, Anna & Byrtus, Hanna & Góra, Małgorzata & Rapacz, Anna & Sałat, Kinga & Koczurkiewicz, Paulina & Pękala, Elżbieta & Obniska, Jolanta & Kamiński, Krzysztof. (2025). Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine‐2,4‐Dione Derivatives with Morpholine Moiety. ChemMedChem. 20. 10.1002/cmdc.202400612.
   19. Kutchner, J. The production process of Levetiracetam: A technical insight into modern API manufacturing. 2025. https://www.chemanalyst.com/NewsAndDeals/NewsDetails/the-production-process-of-levetiracetam-a-technical-insight-into-modern-api-38886
   20. Babu, Ks & Reddy, R. & Naresh, E. & Mohan, K. & Madhusudhan, Gonela & Khagga, Mukkanti. (2013). Enantioselective Synthesis of Antiepileptic Drug: (-)-Levetiracetam—Synthetic Applications of the Versatile New Chiral N-Sulfinimine. Journal of Chemistry. 2013. 10.1155/2013/475032.
   21. Narczyk, Aleksandra & Mrozowicz, Michał & Stecko, Sebastian. (2019). Total synthesis of levetiracetam. Organic & Biomolecular Chemistry. 17. 10.1039/C9OB00111E.
   22. Cai, H., Mangner, T. J., Muzik, O., Wang, M. W., Chugani, D. C., & Chugani, H. T. (2014). Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression. ACS medicinal chemistry letters, 5(10), 1152–1155. https://doi.org/10.1021/ml500285t
   23. Martinez, Juan & Duchowicz, Pablo & Estrada, Mario & Castro, Eduardo. (2012). A Multivariate QSAR Study on the Anticonvulsant Activity of Acetamido-N-Benzylacetamide Derivatives. Influence of Different Molecular Descriptors. Match. 67. 745-758.
   24. Gillard, M., Chatelain, P., & Fuks, B. (2006). Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. European journal of pharmacology, 536(1-2), 102–108. https://doi.org/10.1016/j.ejphar.2006.02.022
   25. Gayke, M., Narode, H., Eppa, G., Bhosale, R. S., & Yadav, J. S. (2022). Synthetic Approaches toward the Synthesis of Brivaracetam: An Antiepileptic Drug. ACS omega, 7(3), 2486–2503. https://doi.org/10.1021/acsomega.1c05378
   26. Behmard, E., Barzegari, E., Najafipour, S., Kouhpayeh, A., Ghasemi, Y., & Asadi-Pooya, A. A. (2022). Efflux dynamics of the antiseizure drug, levetiracetam, through the P-glycoprotein channel revealed by advanced comparative molecular simulations. Scientific reports, 12(1), 13674. https://doi.org/10.1038/s41598-022-17994-3
   27. Schenck, S., Laeremans, T., Steyaert, J., & Brunner, J. D. (2025). Structures of native SV2A reveal the binding mode for tetanus neurotoxin and anti-epileptic racetams. Nature communications, 16(1), 4172. https://doi.org/10.1038/s41467-025-59545-0
   28. Reddy C. Sandeep Kumar, K.K. Azam Khan and C.Nagaraja. "A Review on the Determination of Melting Point Measurement System." International Journal of Advanced Research in Electrical, Flectronics and Instrumentation Engineering 2, No. 5 (2016): 975-979.
   29. Ardita Veseli, Simon Žakelj, Albin Kristl “A review of methods for solubility determination in biopharmaceutical drug characterisation.” Drug Development and Industrial Pharmacy, (2019) ISSN: 0363-9045 (Print) 1520-5762.
   30. Shimaa Baraka, Ahmed M. El Kerdawy “Multimodal Transformer-based Model for Buchwald-Hartwig and Suzuki- Miyaura Reaction Yield Prediction.” arXiv:2204.14062v1 [cs.LG] 27 Apr 2022.
   31. Chandra Babu, K., Buchi Reddy, R., Mukkanti, K., Suresh, K., Madhusudhan, G., Nigam, Satish, Enantioselective Synthesis of Antiepileptic Agent, (−)-Levetiracetam, through Evans Asymmetric Strategy, Journal of Chemistry, 2013, 176512, 5 pages, 2013. https://doi.org/10.1155/2013/176512